Clinical trials: Cytopenias
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Immune Thrombocytopenia
A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients
The aim of this study was to describe real-world treatment patterns and standard of care treatment effectiveness and utilization outcomes in adult primary ITP patients indicated for second-line treatment with any prior…
- Trial name
- NCT07805408
- Where
- United States
- Volunteers
- 3,714 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
The Internal Medicine Department of Haut-Lévêque Hospital (Pr E LAZARO, Pr JL PELLEGRIN, Pr JF VIALLARD) was accredited in 2017 by the Ministry of Health as a Constitutive Reference Center for Autoimmune Cytopenia.
- Conditions
- Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, Autoimmune Neutropenia
- Trial name
- BIOCAI (NCT04005638)
- Testing
- blood sample, urine sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bordeaux
Autoimmune Lymphoproliferative Syndrome
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes.
- Trial name
- NCT06730126
- Testing
- Soquelitinib
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Thrombocytopenia, Pregnancy Related
IVIg Plus Low Dose rhTPO for ITP in Pregnancy
Randomized, open-label, multicenter study to investigate the efficacy and safety of IVIg plus low-dose recombinant thrombopoietin in pregnant patients with corticosteroid or IVIg monotherapy-resistant ITP.
- Trial name
- NCT05634824
- Testing
- intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO), intravenous immunoglobulin
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Thrombotic Microangiopathy, Disorder Related to Bone Marrow Transplantation
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Mortality in the major thrombotic microangiopathies (TMAs), TTP and aHUS, exceeds 90% unless rapidly diagnosed and appropriately treated.
- Trial name
- NCT02604420
- Testing
- eculizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Severe Thrombocytopenia
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
This is an open-label study in which oprelvekin will be administered for the prevention of severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting stable) in adults with cancer who are taking…
- Trial name
- NCT00886743
- Testing
- oprelvekin
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Immune Thrombocytopenia
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP.
- Trial name
- NCT00902018
- Testing
- Eltrombopag, Romiplostim, healthy controls
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Platelet Function, Thrombocytopenia
Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)
Platelet transfusions are routinely administered during neonatal ECMO, with an average of 1.3 platelet transfusions per day being administered while a patient is undergoing ECMO treatment.
- Trial name
- NCT00748878
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Leukemia, CART Therapy
Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever
Pre-neutropenic fever (PNF) (fever following chemotherapy but before developing low white cells) and neutropenic fever (NF) (fever in the setting of low white cells) are very common after chemotherapy for acute leukemia, bone…
- Conditions
- Leukemia, CART Therapy, Transplantation, Stem Cell, Infections, Bacterial
- Trial name
- ELSA-Adult (NCT07051525)
- Testing
- Early antibiotic cessation alert
- Where
- 2 sites in Australia
- Volunteers
- 214 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Anemia, Leukemia
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in…
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00004215
- Testing
- filgrastim, leridistim, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sjogren Syndrome With Other Organ Involvement
Tacrolimus for Thrombocytopenia in SS
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.
- Trial name
- NCT05678335
- Testing
- Hydroxychloroquine, Tacrolimus
- Volunteers
- 54 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Thrombocytopenic Purpura
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Core study: To compare the efficacy of avatrombopag (in addition to standard) of care to eltrombopag (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic…
- Trial name
- NCT01433978
- Testing
- Eltrombopag, Avatrombopag, Standard of care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Hematological Malignancy, Neutropenia
Effect of Body Mass on Filgrastim Pharmacokinetics
Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher…
- Trial name
- NCT01719432
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aaron Cumpston, PharmD, BCOP
Immune Thrombocytopenia
Eltrombopag in Chronic ITP
This study aims to evaluate the efficacy of eltrombopag on the platelet count in pediatric patients with chronic immune thrombocytopenia.
- Trial name
- NCT04102033
- Testing
- Eltrombopag
- Volunteers
- 20 people
- Sponsor
- Assiut University
Breast Neoplasms, Fever
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration of thrombocytopenia and the time to recovery of…
- Conditions
- Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia
- Trial name
- NCT00001338
- Testing
- FLAC chemotherapy with GM-CSF
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Febrile Neutropenia, Hematological Malignancy
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
A multicenter open-label non-inferiority randomized clinical trial comparing the safety (non-inferiority) of short antibiotic treatment (72 hours) with an anti-pseudomonal carbapenem with regard to treatment failure in comparison…
- Trial name
- SHORT (NCT02149329)
- Testing
- Discontinuation of imipenem-cilastatin or meropenem
- Where
- 2 sites in Netherlands
- Volunteers
- 276 people
- Sponsor
- Amsterdam UMC, location VUmc
Pediatric Cancer, Febrile Neutropenia
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
In this pilot study the feasibility continous recording of vital signs in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Oncology, Chemotherapy-induced Neutropenia
- Trial name
- NCT04914702
- Testing
- Everion®, CORE®
- Where
- 2 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Wiskott-Aldrich Syndrome
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
A protocol named as "CIP-2015" for patients with Wiskott-Aldrich Syndrome may reduce the rate of GvHD. The details of the protocal followed with: 1. Conditioning regimen Busulfan 16 mg/kg in total, Fludarabine 160 mg/m2 in total.
- Trial name
- NCT03198195
- Testing
- cyclophosphamide
- Volunteers
- 5 people
- Sponsor
- Capital Research Institute of Pediatrics